ArticleArchives of medical science : AMS2026
Metabolic mediators linking type 1 diabetes mellitus to osteoporosis.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Osteoporosis in Patients with Pre-Existing Diabetes Mellitus and in Women with Estrogen Deficiency: A Molecular and Cellular Perspective.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The causal relationship between type 1 diabetes mellitus (T1DM) and osteoporosis has not been clarified in large prospective cohort studies. This study aimed to assess the causal association between T1DM and osteoporosis, and further identify eligible mediators. Material and methods: We explored the causal relationship between T1DM and osteoporosis by two-sample Mendelian randomization (MR), a method that uses genetic variants as instrumental variables for causal inference. We selected five candidate mediators based on their relevance to metabolic processes in T1DM and bone health, including body mass index (BMI), glycated hemoglobin (HbA1c), cholesterol in medium very low-density lipoprotein particles (M-VLDL-C), saturated fatty acids (SFA), and sex hormone-binding globulin (SHBG), and identified eligible mediators by two-step MR. We validated the correlation of T1DM and mediators with osteoporosis in a UK Biobank (UKB) prospective cohort study. Results: In MR analysis, T1DM was related to a significantly increased risk of osteoporosis (OR = 1.046, 95% CI: 1.015 to 1.079, Conclusions: T1DM may cause osteoporosis by reducing M-VLDL-C and increasing SHBG levels in plasma. The identified mediators may serve as important biomarkers for early detection and treatment of osteoporosis in T1DM patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.